About Verve Therapeutics Inc.

Verve Therapeutics Inc., founded in 2018, is pioneering the application of gene editing technology to prevent and treat cardiovascular disease by permanently modifying genes that control cholesterol production and other cardiovascular risk factors. The company's approach aims to provide one-time treatments for lifelong cardiovascular protection. VERV stock price reflects investor interest in the company's innovative gene editing approach and the significant market opportunity in cardiovascular disease.

Led by CEO Sekar Kathiresan, MD, a renowned cardiovascular geneticist, Verve has assembled a world-class team to develop gene editing therapies for cardiovascular disease prevention. The management team combines deep expertise in cardiovascular genetics with gene editing technology development. Leadership's vision for preventing cardiovascular disease through precision gene editing has been instrumental in advancing the company's programs and influencing VERV stock price potential.

Verve operates by developing in vivo gene editing therapies using base editing technology to permanently lower LDL cholesterol, lipoprotein(a), and other cardiovascular risk factors with single treatments. The company's programs target genetic pathways validated through human genetics studies. With cardiovascular disease remaining the leading cause of death globally, potential for gene editing to provide permanent cardiovascular protection, and Verve's pioneering approach to cardiovascular gene editing, VERV offers investors exposure to potentially transformative cardiovascular therapeutics with significant market opportunity, though gene editing development carries substantial technical and regulatory risks requiring successful clinical validation.